Every year in the U.S., about 40,000 people get a tough form of lung cancer called NSCLC with a KRAS mutation. Even with the best treatments around, most people with this mutation don’t make it past five years.
Dr. Gerber at University of Texas Southwestern Medical Center recently discovered that these cancer cells depend on making lots of fat to survive. If you block that fat-making process, the cancer cells die.
There’s a new drug called TVB-2640 that shuts down the cancer’s fat factory. This study is testing whether TVB-2640 can help people with this hard-to-treat lung cancer live longer and keep the cancer under control.